A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma

• Patrick A. Ott,

  Affiliation Department of Medical Oncology, New York University Cancer Institute, New York, New York, United States of America

  ⨯
• Anne Hamilton,

  Affiliations Royal Prince Alfred Hospital, Sydney Cancer Centre, Sydney, Australia, Sydney Melanoma Unit and University of Sydney, Sydney, Australia

  ⨯
• Amanda Jones,

  Affiliation Department of Medical Oncology, New York University Cancer Institute, New York, New York, United States of America

  ⨯
• Naomi Haas,

  Affiliation Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

  ⨯
• Tsiporah Shore,

  Affiliation Division of Hematology/Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York, United States of America

  ⨯
• Sandra Liddell,

  Affiliation Royal Prince Alfred Hospital, Sydney Cancer Centre, Sydney, Australia

  ⨯
• Paul J. Christos,

  Affiliation Division of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, New York, United States of America

  ⨯
• L. Austin Doyle,

  Affiliation Investigational Drug Branch, National Cancer Institute, Bethesda, Maryland, United States of America

  ⨯
• Michael Millward,

  Affiliation Department of Medical Oncology, Charles Gairdner Hospital and University of Western Australia, Perth, Australia

  ⨯
• Franco M. Muggia,

  Affiliation Department of Medical Oncology, New York University Cancer Institute, New York, New York, United States of America

  ⨯
• Anna C. Pavlick

  * E-mail: anna.pavlick@nyumc.org

  Affiliation Department of Medical Oncology, New York University Cancer Institute, New York, New York, United States of America

  ⨯